{"id":68080,"date":"2026-11-10T08:08:55","date_gmt":"2026-11-10T02:38:55","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=68080"},"modified":"2026-11-10T08:08:59","modified_gmt":"2026-11-10T02:38:59","slug":"interactive-cardiology-mcqs-33-heart-failure","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/","title":{"rendered":"Interactive Cardiology MCQs 33: Heart Failure\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<!-- Cardiology MCQs Part 33 (Full 25 Questions - Heart Failure) - WordPress Safe Custom HTML Block -->\n<script src=\"https:\/\/cdn.tailwindcss.com?plugins=forms,typography,aspect-ratio\"><\/script>\n<script>\n  tailwind.config = { corePlugins: { preflight: false } }\n<\/script>\n\n<div id=\"mcq33-quiz-wrapper\" class=\"font-sans bg-slate-950 text-slate-100 p-4 md:p-8 rounded-3xl max-w-4xl mx-auto shadow-2xl relative overflow-hidden my-8 border border-solid border-cyan-500\/20\" style=\"box-sizing: border-box;\">\n  \n  <div class=\"absolute top-0 left-0 w-full h-full pointer-events-none opacity-10 bg-[radial-gradient(ellipse_at_center,_var(--tw-gradient-stops))] from-cyan-500 via-blue-900 to-slate-950\"><\/div>\n  \n  <div class=\"relative text-center pb-6 border-b border-solid border-cyan-500\/25 mb-8\">\n    <div class=\"inline-block bg-gradient-to-r from-cyan-500 via-blue-600 to-indigo-600 text-white font-black text-xs md:text-sm px-4 py-1.5 rounded-full uppercase tracking-wider shadow-lg mb-3 animate-pulse\">\n      \u26a1 Advanced Cardiology Series &#8211; Part 33\n    <\/div>\n    <h1 class=\"text-3xl md:text-5xl font-extrabold tracking-tight text-transparent bg-clip-text bg-gradient-to-r from-cyan-300 via-blue-400 to-indigo-400 m-0\">\n      Interactive Cardiology MCQs #33\n    <\/h1>\n    <p class=\"text-sm md:text-lg text-slate-300 mt-2 max-w-2xl mx-auto font-medium\">\n      Post-Graduate Level Masterclass: Heart Failure &#038; Cardiomyopathies\n    <\/p>\n  <\/div>\n\n  <div class=\"sticky top-4 z-40 bg-slate-900\/90 backdrop-blur-md border-2 border-solid border-cyan-500\/40 rounded-2xl p-4 mb-8 shadow-xl flex flex-wrap items-center justify-between gap-4\">\n    <div class=\"flex items-center gap-3\">\n      <div class=\"text-3xl\">\ud83e\udec0<\/div>\n      <div>\n        <div class=\"text-[10px] uppercase font-extrabold tracking-widest text-cyan-300\">Live Scoreboard<\/div>\n        <div class=\"text-lg md:text-2xl font-black text-blue-300 flex items-center gap-1\">\n          <span id=\"mcq33-correct-count\">0<\/span><span class=\"text-slate-500 text-sm md:text-lg\">\/ 25 Correct<\/span>\n        <\/div>\n      <\/div>\n    <\/div>\n    <div class=\"flex items-center gap-2 bg-slate-950\/80 px-4 py-2 rounded-xl border border-solid border-slate-800\">\n      <span class=\"text-xs font-bold text-slate-400 uppercase tracking-wider\">Progress:<\/span>\n      <div class=\"w-24 md:w-36 bg-slate-800 h-3 rounded-full overflow-hidden\">\n        <div id=\"mcq33-progress-bar\" class=\"bg-gradient-to-r from-cyan-500 to-blue-500 h-full w-0 transition-all duration-300 rounded-full\"><\/div>\n      <\/div>\n      <span class=\"text-xs font-bold text-blue-300\"><span id=\"mcq33-answered-count\">0<\/span>\/25<\/span>\n    <\/div>\n  <\/div>\n\n  <div class=\"space-y-8 relative\">\n\n    <!-- Q1 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q1<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to the latest universal ACC\/AHA\/HFSA guidelines, foundational Guideline-Directed Medical Therapy (GDMT) for patients with symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF) relies on four primary pillars. Which of the following best represents this quadruple therapy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Ivabradine is a secondary add-on therapy, not one of the foundational four pillars.\">A) ARNI, Beta-blocker, Ivabradine, and a Loop Diuretic.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Digoxin and loop diuretics are for symptom management and select cases, lacking the universal mortality benefit of the four pillars.\">B) ACE Inhibitor, Beta-blocker, Digoxin, and a Loop Diuretic.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The foundational 'quadruple therapy' for HFrEF includes an ARNI (or ACEi\/ARB if ARNI is not feasible), an evidence-based Beta-blocker, a Mineralocorticoid Receptor Antagonist (MRA), and an SGLT2 inhibitor. This combination provides the most substantial reduction in morbidity and all-cause mortality. Reference: 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure.\">C) ARNI (or ACEi\/ARB), Beta-blocker, Mineralocorticoid Receptor Antagonist (MRA), and SGLT2 inhibitor.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Vericiguat is a newer adjunctive therapy for high-risk patients, not a universal first-line pillar.\">D) ARB, Beta-blocker, MRA, and Vericiguat.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q2 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q2<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In a patient newly started on Sacubitril\/Valsartan (an ARNI) for HFrEF, how will the circulating levels of B-type Natriuretic Peptide (BNP) and N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) typically change, and why?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Both do not decrease identically; Sacubitril specifically alters BNP metabolism.\">A) Both BNP and NT-proBNP will decrease due to reduced myocardial wall stress.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Sacubitril is a neprilysin inhibitor. Neprilysin degrades BNP, but NOT NT-proBNP. Therefore, inhibiting neprilysin artificially elevates circulating BNP levels (reflecting the drug's action, not worsening heart failure). Conversely, NT-proBNP decreases, accurately reflecting the therapeutic reduction in myocardial wall stress. Clinicians must use NT-proBNP to monitor HF status in patients on an ARNI. Reference: PARADIGM-HF Trial Biomarker Analysis.\">B) BNP will increase (due to neprilysin inhibition), while NT-proBNP will decrease (due to improved hemodynamics).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"NT-proBNP decreases because it is not a substrate for neprilysin, while BNP increases.\">C) BNP will decrease, while NT-proBNP will increase.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ARNI therapy profoundly affects these biomarkers; they do not remain unchanged.\">D) Both BNP and NT-proBNP will remain unchanged as ARNI only affects atrial natriuretic peptide (ANP).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q3 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q3<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The EMPEROR-Preserved and DELIVER trials revolutionized the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). Which class of medications was the first to demonstrate a significant reduction in heart failure hospitalizations and cardiovascular death in this population?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"ARNIs showed marginal\/borderline benefit in PARAGON-HF, missing the primary endpoint for the broad HFpEF population.\">A) Angiotensin Receptor-Neprilysin Inhibitors (ARNI).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"MRAs (TOPCAT trial) showed regional variations and did not definitively meet primary endpoints globally for HFpEF.\">B) Mineralocorticoid Receptor Antagonists (MRA).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"SGLT2 inhibitors (Empagliflozin in EMPEROR-Preserved and Dapagliflozin in DELIVER) were the first pharmacological agents to demonstrate a robust, statistically significant reduction in the composite endpoint of cardiovascular death and heart failure hospitalizations in patients with HFpEF, regardless of the presence of diabetes. Reference: EMPEROR-Preserved (NEJM 2021).\">C) Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Beta-blockers have not shown mortality or morbidity benefits in pure HFpEF.\">D) Beta-blockers.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q4 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q4<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A 68-year-old male with ischemic cardiomyopathy remains highly symptomatic (NYHA Class III) on maximally tolerated optimal medical therapy. His ECG shows normal sinus rhythm. According to current guidelines, what are the strict criteria for a Class I indication for Cardiac Resynchronization Therapy (CRT-D)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A QRS of 130 ms with LBBB is a Class IIa indication, not a Class I indication.\">A) LVEF less than or equal to 35 percent, Left Bundle Branch Block (LBBB), and QRS duration greater than or equal to 130 ms.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The strongest (Class I) indication for Cardiac Resynchronization Therapy (CRT) is for patients who have an LVEF less than or equal to 35 percent, normal sinus rhythm, a typical Left Bundle Branch Block (LBBB) morphology, and a QRS duration of greater than or equal to 150 ms, while remaining symptomatic on optimal medical therapy. Reference: AHA\/ACC\/HRS Guideline for Management of Heart Failure and Arrhythmias.\">B) LVEF less than or equal to 35 percent, Left Bundle Branch Block (LBBB), and QRS duration greater than or equal to 150 ms.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Non-LBBB morphologies (like RBBB) with wide QRS generally carry a Class IIa or IIb indication, as they respond less predictably to CRT.\">C) LVEF less than or equal to 35 percent, Non-LBBB pattern, and QRS duration greater than or equal to 150 ms.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"An LVEF of 40 percent (HFmrEF) does not currently meet standard Class I criteria for CRT.\">D) LVEF less than or equal to 40 percent, LBBB, and QRS duration greater than or equal to 150 ms.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q5 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q5<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Ivabradine is indicated for select patients with HFrEF to reduce heart failure hospitalizations (based on the SHIFT trial). What is the exact mechanism of action of this medication?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes the action of cardiac glycosides (like Digoxin), which are positive inotropes.\">A) Inhibition of the Na+\/K+ ATPase pump, increasing intracellular calcium.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Ivabradine selectively inhibits the 'funny' current (I_f) channel in the sinoatrial (SA) node. This prolongs diastolic depolarization, effectively slowing the heart rate without negatively impacting myocardial contractility (no negative inotropic effect) or blood pressure. It is indicated when patients in sinus rhythm have a resting HR greater than or equal to 70 bpm despite max tolerated beta-blockers. Reference: SHIFT Trial (Lancet).\">B) Selective inhibition of the &#8216;funny&#8217; current (I_f) channel in the sinoatrial node.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes a beta-blocker, not Ivabradine.\">C) Antagonism of beta-1 adrenergic receptors in the myocardium.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Vericiguat, a completely different heart failure medication.\">D) Direct stimulation of soluble guanylate cyclase (sGC) independent of nitric oxide.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q6 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q6<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Vericiguat was approved for high-risk patients with worsening HFrEF based on the VICTORIA trial. What is its pharmacological mechanism?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Omecamtiv mecarbil (evaluated in the GALACTIC-HF trial).\">A) A direct cardiac myosin activator that increases systolic ejection time.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Neprilysin inhibition is the mechanism of Sacubitril.\">B) Inhibition of neprilysin, preventing the breakdown of vasoactive peptides.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Vericiguat is a novel, oral soluble guanylate cyclase (sGC) stimulator. In heart failure, endothelial dysfunction leads to deficient nitric oxide (NO) and reduced sGC activity, lowering intracellular cGMP. Vericiguat directly stimulates sGC independent of NO, increasing cGMP, which promotes myocardial relaxation and systemic vasodilation. Reference: VICTORIA Trial (NEJM).\">C) A soluble guanylate cyclase (sGC) stimulator that increases intracellular cGMP.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Ivabradine.\">D) Selective blockade of the I_f current in the SA node.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q7 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q7<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Under the SCAI (Society for Cardiovascular Angiography and Interventions) clinical staging for Cardiogenic Shock, how is a patient in &#8220;Stage C&#8221; defined?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Stage A ('At risk').\">A) A patient at risk for cardiogenic shock but currently hemodynamically stable without hypoperfusion.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Stage B ('Beginning' shock).\">B) A patient with relative hypotension and tachycardia but no clinical evidence of hypoperfusion.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"SCAI Stage C represents 'Classic' cardiogenic shock. These patients present with hypoperfusion (e.g., altered mentation, cold extremities, high lactate, low urine output) and require pharmacological interventions (inotropes\/vasopressors) or mechanical circulatory support (MCS) to maintain hemodynamics, but they are not rapidly deteriorating (which would be Stage D) or in extremis\/cardiac arrest (Stage E). Reference: SCAI Clinical Expert Consensus Statement on the Classification of Cardiogenic Shock.\">C) A patient with clinical hypoperfusion requiring pharmacological inotropes\/vasopressors or mechanical support.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Stage E ('Extremis'), involving ongoing cardiac arrest or ECMO.\">D) A patient in refractory cardiac arrest requiring ongoing CPR and immediate ECMO.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q8 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q8<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Patients supported with continuous-flow Left Ventricular Assist Devices (cf-LVADs) frequently develop gastrointestinal bleeding. What unique pathophysiological mechanism, caused directly by the continuous-flow physiology, drives this complication?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"While device thrombosis occurs and consumes platelets, the specific driver of GI bleeds is an acquired factor defect due to shear stress.\">A) Mechanical destruction of platelets leading to profound thrombocytopenia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Continuous-flow LVADs create high shear stress that unfurls and destroys large von Willebrand Factor (vWF) multimers. This creates an 'acquired von Willebrand syndrome'. Concurrently, the loss of pulsatile blood flow causes mucosal hypoxia in the gut, promoting the formation of arteriovenous malformations (AVMs). The combination of AVMs and acquired vWF deficiency leads to frequent, severe GI bleeding (a physiology identical to Heyde's Syndrome in severe aortic stenosis). Reference: ISHLT Guidelines for Mechanical Circulatory Support.\">B) High shear stress causing acquired von Willebrand syndrome and loss of pulsatility causing GI arteriovenous malformations.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Warfarin causes bleeding, but the unique pathophysiology of LVAD bleeding goes beyond just standard anticoagulation.\">C) Supratherapeutic dosing of Warfarin required to prevent pump thrombosis directly eroding the gastric mucosa.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is not a recognized mechanism for LVAD-associated GI bleeding.\">D) The inflow cannula directly obstructing the celiac artery, causing ischemic colitis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q9 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q9<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient with Acute Decompensated Heart Failure presents with cool extremities, altered mentation, and significant peripheral edema. Based on the Forrester Hemodynamic Classification, which subset is this patient in, and what is the primary therapeutic goal?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Warm and Wet is Subset II, which is treated primarily with diuretics and vasodilators.\">A) Subset II (Warm and Wet); treat with aggressive IV loop diuretics and vasodilators.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Cold and Dry is Subset III, which often requires fluid administration and inotropes, but this patient has edema (Wet).\">B) Subset III (Cold and Dry); treat with cautious fluid boluses and inotropes.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The patient has signs of hypoperfusion (cool extremities, altered mentation = 'Cold') and congestion (peripheral edema = 'Wet'). This places them in Forrester Subset IV (Cold and Wet), which carries the highest mortality. Treatment is complex and usually requires inotropes\/vasopressors to support perfusion, followed by cautious diuresis or mechanical circulatory support once hemodynamics are stabilized. Reference: Forrester Classification of Heart Failure.\">C) Subset IV (Cold and Wet); treat with inotropes, vasodilators (if BP allows), and diuretics.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Warm and Dry is Subset I, which is the compensated normal state requiring only oral maintenance therapy.\">D) Subset I (Warm and Dry); treat with optimization of oral GDMT.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q10 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q10<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In diagnosing Transthyretin Cardiac Amyloidosis (ATTR-CM), a Technetium-99m Pyrophosphate (Tc-99m PYP) scan is highly specific. Under what exact conditions can a positive PYP scan confirm ATTR-CM without requiring an endomyocardial biopsy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A biopsy is always required if AL amyloidosis is suspected or cannot be ruled out.\">A) A positive scan confirms ATTR-CM in all patients regardless of laboratory results.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Non-invasive diagnosis of ATTR Cardiac Amyloidosis is possible if the Tc-99m PYP scan shows Grade 2 or 3 myocardial uptake AND the patient tests entirely negative for monoclonal proteins (using serum free light chains, and serum\/urine immunofixation electrophoresis). AL amyloidosis (which is a hematological malignancy) can also show mild\/moderate PYP uptake and MUST be completely excluded first. Reference: AHA Scientific Statement on Cardiac Amyloidosis.\">B) Grade 2 or 3 myocardial uptake AND completely normal serum\/urine immunofixation and free light chain assays (ruling out AL amyloid).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"A cardiac MRI is highly suggestive but is not the specific criteria that allows bypassing the biopsy; ruling out AL amyloid is the key.\">C) Grade 2 or 3 myocardial uptake combined with typical Late Gadolinium Enhancement on Cardiac MRI.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Apical sparing is an echo feature, but does not replace the requirement to exclude monoclonal proteins.\">D) Grade 1 myocardial uptake combined with an echocardiogram showing &#8216;apical sparing&#8217; of longitudinal strain.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q11 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q11<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Based on the ATTR-ACT trial, Tafamidis is the first targeted therapy approved to reduce cardiovascular mortality in Transthyretin Cardiac Amyloidosis (ATTR-CM). What is its specific mechanism of action?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Patisiran or Inotersen (RNA interference therapies).\">A) It silences the TTR gene in the liver via small interfering RNA (siRNA).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Transthyretin (TTR) circulates as a tetramer. In ATTR amyloidosis, the tetramer becomes unstable, dissociates into monomers, and misfolds into amyloid fibrils that deposit in the heart. Tafamidis binds specifically to the TTR tetramer, stabilizing it and preventing its dissociation and subsequent amyloidogenesis. Reference: ATTR-ACT Trial (NEJM).\">B) It binds to and stabilizes the circulating transthyretin tetramer, preventing its dissociation into amyloidogenic monomers.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"There is currently no approved therapy that reliably dissolves existing amyloid fibrils in the heart.\">C) It directly dissolves established amyloid fibrils deposited within the myocardial extracellular matrix.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes monoclonal antibody therapies used for AL amyloidosis (e.g., Daratumumab).\">D) It acts as a monoclonal antibody that targets and destroys the plasma cells producing the misfolded proteins.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q12 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q12<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Mavacamten was recently approved for symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) based on the EXPLORER-HCM trial. What is its mechanism of action, and what is its most critical potential adverse effect requiring strict echocardiographic monitoring?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"It is not a calcium channel blocker; its mechanism is highly specific to the sarcomere.\">A) It is a potent non-dihydropyridine calcium channel blocker; risk of severe AV block.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Mavacamten is a first-in-class cardiac myosin inhibitor. It reduces the number of actin-myosin cross-bridges (the source of the hypercontractility in HCM), relieving the LVOT obstruction and improving hemodynamics. Because it directly suppresses myocardial contractility, its most critical adverse effect is a potentially severe reduction in Left Ventricular Ejection Fraction (causing heart failure), requiring strict, protocolized REMS echocardiographic monitoring. Reference: EXPLORER-HCM Trial.\">B) It is a cardiac myosin inhibitor; risk of severe reduction in Left Ventricular Ejection Fraction (LVEF).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"It inhibits, rather than activates, cardiac myosin. Activators (like Omecamtiv) are for HFrEF.\">C) It is a cardiac myosin activator; risk of inducing sustained ventricular tachycardia.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"It does not specifically target structural septal reduction (like alcohol septal ablation does).\">D) It induces targeted apoptosis of the hypertrophied septum; risk of ventricular septal rupture.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q13 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q13<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          According to the DIG trial, what is the specific long-term clinical benefit of adding Digoxin to patients with HFrEF in normal sinus rhythm who remain symptomatic on standard therapy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Digoxin notably does NOT reduce overall mortality.\">A) It significantly reduces all-cause mortality and sudden cardiac death.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The landmark DIG (Digitalis Investigation Group) trial demonstrated that in patients with HFrEF in normal sinus rhythm, Digoxin significantly reduces the rate of hospitalizations for worsening heart failure and improves symptoms. However, it has a completely neutral effect on all-cause mortality (it does not make patients live longer). Reference: The DIG Trial (NEJM).\">B) It significantly reduces heart failure hospitalizations but has no effect on overall mortality.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Digoxin is highly arrhythmogenic, especially in toxicity or hypokalemia, and does not reduce arrhythmias.\">C) It reduces the incidence of ventricular arrhythmias by increasing vagal tone.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Digoxin increases intracellular calcium (positive inotrope); it does not act as a negative inotrope.\">D) It acts as a negative inotrope, allowing better diastolic filling and reducing mortality.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q14 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q14<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Iron deficiency is highly prevalent in Heart Failure and worsens symptoms independent of anemia. According to the AFFIRM-AHF and IRONMAN trials, what is the guideline-directed threshold for administering Intravenous Iron (e.g., Ferric Carboxymaltose) in HFrEF?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This represents severe anemia, but iron supplementation thresholds in HF are much more aggressive and do not require the hemoglobin to be this low.\">A) Hemoglobin less than 9 g\/dL regardless of ferritin levels.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Current HF guidelines strongly recommend IV iron (Ferric Carboxymaltose or Ferric Derisomaltose) to improve symptoms and reduce HF hospitalizations in HFrEF patients with iron deficiency. This is defined as a serum Ferritin less than 100 ng\/mL, OR a Ferritin between 100-299 ng\/mL combined with a Transferrin Saturation (TSAT) less than 20 percent. Oral iron has proven ineffective in this population. Reference: 2022 AHA\/ACC\/HFSA Guidelines.\">B) Serum Ferritin less than 100 ng\/mL, OR Ferritin 100-299 ng\/mL with a Transferrin Saturation (TSAT) less than 20 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Oral iron was studied in the IRONOUT HF trial and found to be ineffective in HFrEF due to hepcidin-mediated malabsorption.\">C) Iron deficiency should be treated primarily with oral Ferrous Sulfate before escalating to IV iron.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Ferritin below 30 is the WHO definition for standard iron deficiency, but HF uses a much higher threshold due to systemic inflammation.\">D) Serum Ferritin less than 30 ng\/mL with a TSAT less than 10 percent.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q15 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q15<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Peripartum Cardiomyopathy is a rare, life-threatening systolic dysfunction occurring towards the end of pregnancy or months postpartum. Recent evidence suggests that abnormal cleavage of a specific hormone drives the endothelial and myocardial toxicity. Which drug is utilized specifically to block this pathway?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Oxytocin causes uterine contractions; it is not the primary driver of the myocardial toxicity in PPCM.\">A) Oxytocin antagonists (e.g., Atosiban).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Current pathophysiology of Peripartum Cardiomyopathy (PPCM) heavily implicates the abnormal cleavage of Prolactin into a 16-kDa highly angiostatic and cardiotoxic fragment. Bromocriptine (a dopamine agonist) blocks the pituitary release of prolactin, eliminating the source of this toxic fragment. It is increasingly used alongside standard GDMT for severe PPCM (accompanied by anticoagulation, as it increases thrombotic risk). Reference: ESC Guidelines on Cardiovascular Diseases during Pregnancy.\">B) Bromocriptine, to block the release and subsequent toxic cleavage of Prolactin.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"hCG is the pregnancy hormone, but its cleavage is not the established cause of PPCM.\">C) Mifepristone, to block the cardiotoxic effects of Human Chorionic Gonadotropin (hCG).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Progesterone is not the driver of PPCM.\">D) High-dose Progesterone, to stabilize the myocardial endothelium.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q16 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q16<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Stress-induced cardiomyopathy (Takotsubo syndrome) frequently mimics an acute anterior STEMI. What is the pathognomonic echocardiographic or ventriculographic feature of the classic form of this disease?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This pattern is occasionally seen in 'reverse Takotsubo', but the classic, most common form is apical ballooning.\">A) Akinesis of the basal segments with hyperkinesis of the apical segments.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The classic 'Takotsubo' (Japanese octopus trap) appearance is defined by profound akinesis or dyskinesis of the Left Ventricular apex and mid-ventricular segments, accompanied by compensatory hyperkinesis of the basal segments. This results in the characteristic 'apical ballooning' appearance during systole, usually triggered by a massive sympathetic catecholamine surge. Reference: International Takotsubo Registry.\">B) Severe akinesis\/dyskinesis of the apical and mid-ventricular segments with hyperkinesis of the basal segments.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Diffuse global hypokinesis describes a global toxic or viral myocarditis, lacking the focal ballooning of Takotsubo.\">C) Diffuse, uniform global hypokinesis of all ventricular segments without regional variation.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Asymmetrical septal hypertrophy is the hallmark of Hypertrophic Cardiomyopathy (HCM), not Takotsubo.\">D) Asymmetrical septal hypertrophy with systolic anterior motion (SAM) of the mitral valve.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q17 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q17<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A patient migrating from South America presents with progressive heart failure, complete Right Bundle Branch Block (RBBB) with Left Anterior Fascicular Block (LAFB), and a distinct apical aneurysm on echocardiography. What is the most likely infectious etiology?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Lyme carditis typically presents with reversible AV blocks, not chronic apical aneurysms and RBBB.\">A) Borrelia burgdorferi (Lyme Carditis).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Chagas disease, caused by the parasite Trypanosoma cruzi (endemic to Latin\/South America), frequently leads to a chronic dilated cardiomyopathy. The classic triad of cardiac Chagas includes: 1) Conduction system disease (especially RBBB with LAFB), 2) Ventricular arrhythmias, and 3) A pathognomonic Left Ventricular Apical Aneurysm (which is highly thrombogenic). Reference: AHA Scientific Statement on Chagas Cardiomyopathy.\">B) Trypanosoma cruzi (Chagas Cardiomyopathy).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Coxsackievirus B causes viral myocarditis, which usually results in global dilation without the classic apical aneurysm and RBBB\/LAFB combo.\">C) Coxsackievirus B.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Toxoplasma can cause myocarditis in immunocompromised patients, but not this classic geographical\/anatomical presentation.\">D) Toxoplasma gondii.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q18 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q18<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Patients with severe HFrEF often exhibit Cheyne-Stokes respiration (a form of Central Sleep Apnea) during sleep. According to the SERVE-HF trial, which intervention is strictly CONTRAINDICATED in this specific population because it increases all-cause and cardiovascular mortality?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"CPAP is generally safe and often used for obstructive sleep apnea in HF patients.\">A) Continuous Positive Airway Pressure (CPAP).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The SERVE-HF trial investigated the use of Adaptive Servo-Ventilation (ASV) to treat predominant Central Sleep Apnea (Cheyne-Stokes respiration) in patients with HFrEF (LVEF less than or equal to 45%). The trial was stopped early because ASV significantly INCREASED all-cause and cardiovascular mortality in these patients. It is now strictly contraindicated. Reference: SERVE-HF Trial (NEJM).\">B) Adaptive Servo-Ventilation (ASV).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Nocturnal oxygen is a benign, supportive therapy and is not contraindicated.\">C) Nocturnal supplemental oxygen therapy.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Acetazolamide can stimulate respiration, but is not the device-based therapy proven fatal in SERVE-HF.\">D) Acetazolamide.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q19 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q19<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The COAPT and MITRA-FR trials evaluated percutaneous edge-to-edge mitral valve repair (MitraClip) for secondary (functional) mitral regurgitation in HFrEF. The trials yielded conflicting results. Based on current understanding, which patient profile (demonstrated in COAPT) derives the greatest mortality benefit from MitraClip?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes 'proportionate' MR (seen in MITRA-FR), where the MR is just a byproduct of a massively ruined ventricle. Fixing the valve here doesn't help the dead ventricle.\">A) Patients with extremely dilated left ventricles (LVEDV greater than 200 mL) and mild-to-moderate MR.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"The COAPT trial succeeded where MITRA-FR failed because it selected patients with 'disproportionate' MR. These patients have severe mitral regurgitation (large Effective Regurgitant Orifice Area - EROA) that is out of proportion to the degree of Left Ventricular dilation (the LV is not yet massively dilated\/destroyed). In these patients, the MR itself is driving the pathology, and fixing it with a MitraClip drastically reduces mortality and hospitalizations. Reference: COAPT Trial (NEJM).\">B) Patients with severe MR (large regurgitant orifice) that is &#8216;disproportionate&#8217; to a relatively preserved, less dilated Left Ventricle.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"MitraClip is not for primary\/structural MR caused by chordal rupture; that requires surgical repair or replacement.\">C) Patients with acute primary MR due to papillary muscle or chordal rupture.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"NYHA Class I patients are asymptomatic and generally do not undergo invasive MitraClip for secondary MR.\">D) Patients who are completely asymptomatic (NYHA Class I) regardless of LV size.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q20 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q20<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          A previously healthy 40-year-old presents in rapidly progressive cardiogenic shock. ECG shows ventricular tachycardia. An echocardiogram shows a thickened, globally hypokinetic myocardium. Endomyocardial biopsy reveals multinucleated giant cells and widespread myocardial necrosis without sarcoid granulomas. What is the diagnosis and appropriate therapy?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Eosinophilic myocarditis has eosinophils (hypersensitivity), not giant cells, and is treated with high-dose steroids.\">A) Eosinophilic Myocarditis; treat with immediate withdrawal of the offending drug and high-dose steroids.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"This is the classic presentation of Idiopathic Giant Cell Myocarditis (IGCM), a highly lethal, rapidly progressive autoimmune disease. The biopsy hallmark is multinucleated giant cells with extensive necrosis (distinguishing it from the non-necrotizing granulomas of cardiac sarcoidosis). It requires immediate, aggressive immunosuppression (Cyclosporine, steroids, ATG) and early evaluation for mechanical support or heart transplantation. Reference: AHA Statement on Myocarditis.\">B) Idiopathic Giant Cell Myocarditis; treat with aggressive multidrug immunosuppression and prepare for mechanical support\/transplant.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Viral myocarditis biopsy shows lymphocytic infiltrates, not giant cells, and responds poorly to aggressive immunosuppression.\">C) Coxsackie Viral Myocarditis; treat supportively as it will likely resolve spontaneously.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Cardiac sarcoidosis has non-caseating granulomas with giant cells, but usually without the massive, rapid necrosis seen in IGCM.\">D) Cardiac Sarcoidosis; treat with Methotrexate and a pacemaker.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q21 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q21<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Danon disease is a rare, highly penetrant genetic disorder that phenotypically mimics severe Hypertrophic Cardiomyopathy. Which of the following constellations of findings is the classic hallmark of Danon disease?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Danon disease is an X-linked dominant lysosomal storage disorder caused by a mutation in the LAMP2 gene. It is characterized by the classic clinical triad of extreme Left Ventricular Hypertrophy (often progressing rapidly to heart failure), skeletal myopathy, and intellectual disability. The ECG classically shows a pre-excitation (Wolff-Parkinson-White) pattern. Reference: Genetics of Cardiomyopathies.\">A) LAMP2 mutation, extreme Left Ventricular Hypertrophy, skeletal myopathy, and a WPW pattern on ECG.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Fabry disease, a different lysosomal storage disorder (GLA mutation).\">B) GLA mutation, concentric LVH, angiokeratomas, and neuropathic pain.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes classic sarcomeric Hypertrophic Cardiomyopathy (HCM), not Danon disease.\">C) MYBPC3 mutation, asymmetrical septal hypertrophy, and Systolic Anterior Motion (SAM) of the mitral valve.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This describes Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), which affects the PKP2 desmosomal gene.\">D) PKP2 mutation, fibrofatty replacement of the right ventricle, and Epsilon waves on ECG.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q22 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q22<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In cardio-oncology, different chemotherapeutic agents cause distinct patterns of cardiotoxicity. How does Type I cardiotoxicity (e.g., Anthracyclines like Doxorubicin) fundamentally differ from Type II cardiotoxicity (e.g., Trastuzumab)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Type 1 (Anthracyclines) causes irreversible death, while Type 2 (Trastuzumab) causes reversible dysfunction.\">A) Type I causes reversible myocardial stunning, while Type II causes irreversible, dose-dependent myocardial necrosis.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Type I cardiotoxicity (Anthracyclines) is dose-dependent, cumulative, and characterized by irreversible myocardial cell death (necrosis\/apoptosis) and permanent structural remodeling. Type II cardiotoxicity (Trastuzumab\/Herceptin) is largely dose-independent, characterized by cellular dysfunction without necrosis, and is typically reversible upon discontinuation of the drug. Reference: ESC Guidelines on Cardio-Oncology.\">B) Type I is dose-dependent and causes irreversible myocardial cell death, whereas Type II is dose-independent and largely reversible.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Neither drug exclusively affects the right ventricle; both primarily manifest as LV dysfunction.\">C) Type I exclusively affects the Right Ventricle, whereas Type II exclusively targets the Left Ventricle.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Type I affects the myocardium directly, not via the pericardium.\">D) Type I is an autoimmune pericarditis, whereas Type II is a direct toxic myocarditis.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q23 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q23<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          The definition and classification of heart failure have been updated. What is the specific Left Ventricular Ejection Fraction (LVEF) range that defines Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF)?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"LVEF less than or equal to 40% is defined as HFrEF.\">A) LVEF less than or equal to 40 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"According to the Universal Definition and Classification of Heart Failure (adopted by AHA\/ACC\/HFSA and ESC), Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF) is strictly defined as an LVEF between 41 percent and 49 percent. (HFrEF is less than or equal to 40%, and HFpEF is greater than or equal to 50%). Patients in the HFmrEF category often benefit from the same therapies as HFrEF patients. Reference: Universal Definition of HF.\">B) LVEF 41 percent to 49 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"LVEF greater than or equal to 50% defines HFpEF.\">C) LVEF 50 percent to 59 percent.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This crosses the boundary between HFrEF and HFmrEF.\">D) LVEF 35 percent to 45 percent.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q24 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q24<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          Omecamtiv mecarbil was evaluated in the GALACTIC-HF trial for the treatment of HFrEF. How does this novel agent improve cardiac function?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the mechanism of Mavacamten, used for Hypertrophic Cardiomyopathy.\">A) By inhibiting cardiac myosin and reducing hypercontractility.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"Omecamtiv mecarbil is a selective cardiac myosin activator. It binds directly to the cardiac myosin head, accelerating its transition into the force-producing state. This increases the number of active actin-myosin cross-bridges during systole, thereby prolonging systolic ejection time and improving stroke volume without increasing intracellular calcium or myocardial oxygen demand (unlike traditional inotropes like dobutamine). Reference: GALACTIC-HF Trial.\">B) By selectively activating cardiac myosin, prolonging systolic ejection time without increasing intracellular calcium.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the mechanism of classic inodilators like Milrinone (PDE3 inhibitor).\">C) By inhibiting phosphodiesterase-3 (PDE3), raising intracellular cAMP.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"This is the mechanism of Vericiguat.\">D) By stimulating soluble guanylate cyclase (sGC) to increase cGMP.<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n    <!-- Q25 -->\n    <div class=\"quiz-card bg-slate-900\/60 border border-solid border-slate-800 rounded-2xl p-5 md:p-6 shadow-lg transition-all duration-300\" data-answered=\"false\">\n      <div class=\"flex items-start gap-3 mb-4\">\n        <span class=\"bg-cyan-950 text-cyan-300 font-extrabold px-3 py-1.5 rounded-lg text-sm border border-solid border-cyan-500\/30\">Q25<\/span>\n        <h3 class=\"text-lg md:text-xl font-bold text-slate-100 m-0 leading-snug\">\n          In patients with severe Cor Pulmonale (Right Heart Failure) due to WHO Group 2 Pulmonary Hypertension (PH due to Left Heart Disease), which specific pulmonary vasodilator therapy is indicated?\n        <\/h3>\n      <\/div>\n      <div class=\"grid grid-cols-1 md:grid-cols-2 gap-3 mb-4\">\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Sildenafil (PDE5 inhibitor) is for Group 1 PAH and can cause fatal pulmonary edema in Group 2.\">A) Sildenafil (PDE5 inhibitor).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Bosentan (ERA) is for Group 1 PAH, not Group 2.\">B) Bosentan (Endothelin Receptor Antagonist).<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"true\" data-explanation=\"A trick question: Specific pulmonary arterial vasodilators (like PDE5 inhibitors, ERAs, and Prostacyclins) are strictly contraindicated or not recommended in WHO Group 2 Pulmonary Hypertension (PH due to Left Heart Disease). Dilating the pulmonary bed without fixing the left-sided obstruction floods the left atrium, causing flash pulmonary edema. The ONLY indicated treatment for Group 2 PH is aggressive optimization of the underlying left heart disease (e.g., diuretics, GDMT, valve repair). Reference: ESC\/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension.\">C) None; pulmonary vasodilators are strictly contraindicated as they can precipitate flash pulmonary edema. Optimize Left Heart GDMT.<\/button>\n        <button type=\"button\" class=\"opt-btn text-left p-4 rounded-xl border-2 border-solid border-slate-800 bg-slate-950 hover:bg-slate-900 transition-all text-sm md:text-base font-semibold text-slate-300 cursor-pointer\" data-correct=\"false\" data-explanation=\"Epoprostenol is a potent prostacyclin for severe Group 1 PAH, and would flood the left heart in Group 2.\">D) Intravenous Epoprostenol (Prostacyclin analogue).<\/button>\n      <\/div>\n      <div class=\"feedback-box hidden p-4 rounded-xl text-sm md:text-base leading-relaxed\"><\/div>\n    <\/div>\n\n  <\/div>\n<\/div>\n\n<script>\n  let mcq33Correct = 0;\n  let mcq33Answered = 0;\n  const mcq33Total = 25;\n\n  document.querySelectorAll('#mcq33-quiz-wrapper .quiz-card').forEach(card => {\n    const buttons = card.querySelectorAll('.opt-btn');\n    buttons.forEach(btn => {\n      btn.addEventListener('click', function() {\n        if (card.getAttribute('data-answered') === 'true') return;\n        card.setAttribute('data-answered', 'true');\n        mcq33Answered++;\n\n        document.getElementById('mcq33-answered-count').innerText = mcq33Answered;\n        const pct = (mcq33Answered \/ mcq33Total) * 100;\n        document.getElementById('mcq33-progress-bar').style.width = pct + '%';\n\n        buttons.forEach(b => {\n          b.disabled = true;\n          b.classList.remove('hover:bg-slate-900', 'cursor-pointer');\n          b.classList.add('opacity-50', 'cursor-not-allowed');\n        });\n\n        const isCorrect = this.getAttribute('data-correct') === 'true';\n        const explanation = this.getAttribute('data-explanation');\n\n        if (isCorrect) {\n          mcq33Correct++;\n          document.getElementById('mcq33-correct-count').innerText = mcq33Correct;\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-teal-950\/80', 'border-teal-500', 'text-teal-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10004; CORRECT!<\/span>';\n        } else {\n          this.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n          this.classList.add('bg-cyan-950\/80', 'border-blue-500', 'text-cyan-200', 'opacity-100', 'border-2');\n          this.innerHTML += ' <span class=\"font-bold\">&#10006; INCORRECT<\/span>';\n\n          buttons.forEach(b => {\n            if (b.getAttribute('data-correct') === 'true') {\n              b.classList.remove('opacity-50', 'border-slate-800', 'bg-slate-950');\n              b.classList.add('bg-teal-950\/40', 'border-teal-500\/55', 'text-teal-200', 'opacity-100', 'border-2');\n              b.innerHTML += ' <span class=\"font-bold\">&#10004; (Correct)<\/span>';\n            }\n          });\n        }\n\n        const feedback = card.querySelector('.feedback-box');\n        feedback.innerHTML = `\n          <div class=\"font-extrabold uppercase tracking-widest text-xs mb-2 ${isCorrect ? 'text-teal-400' : 'text-cyan-400'}\">\n            ${isCorrect ? 'Clinical Explanation & Reference' : 'Explanation, Correct Answer & Reference'}\n          <\/div>\n          <p class=\"m-0\">${explanation}<\/p>\n        `;\n        feedback.classList.remove('hidden');\n        feedback.classList.add('block', isCorrect ? 'bg-teal-950\/45' : 'bg-cyan-950\/20', 'border-2', 'border-solid', isCorrect ? 'border-teal-500\/30' : 'border-blue-500\/30', 'text-slate-200', 'mt-4');\n      });\n    });\n  });\n<\/script>\n","protected":false},"excerpt":{"rendered":"<p>\u26a1 Advanced Cardiology Series &#8211; Part 33 Interactive Cardiology MCQs #33 Post-Graduate Level Masterclass: Heart Failure &#038; Cardiomyopathies \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 According to the latest universal ACC\/AHA\/HFSA guidelines, foundational Guideline-Directed Medical Therapy (GDMT) for patients with symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF) relies on four primary pillars. [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":68081,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","nfd_image_url":"","nfd_onboarding_generated":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-68080","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Interactive Cardiology MCQs 33: Heart Failure\u00a0 - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interactive Cardiology MCQs 33: Heart Failure\u00a0 - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"\u26a1 Advanced Cardiology Series &#8211; Part 33 Interactive Cardiology MCQs #33 Post-Graduate Level Masterclass: Heart Failure &#038; Cardiomyopathies \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 According to the latest universal ACC\/AHA\/HFSA guidelines, foundational Guideline-Directed Medical Therapy (GDMT) for patients with symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF) relies on four primary pillars. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T02:38:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-10T02:38:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1340\" \/>\n\t<meta property=\"og:image:height\" content=\"727\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Interactive Cardiology MCQs 33: Heart Failure\u00a0\",\"datePublished\":\"2026-11-10T02:38:55+00:00\",\"dateModified\":\"2026-11-10T02:38:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/\"},\"wordCount\":2026,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/\",\"name\":\"Interactive Cardiology MCQs 33: Heart Failure\u00a0 - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg\",\"datePublished\":\"2026-11-10T02:38:55+00:00\",\"dateModified\":\"2026-11-10T02:38:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg\",\"width\":1340,\"height\":727},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/interactive-cardiology-mcqs-33-heart-failure\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interactive Cardiology MCQs 33: Heart Failure\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interactive Cardiology MCQs 33: Heart Failure\u00a0 - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/","og_locale":"en_US","og_type":"article","og_title":"Interactive Cardiology MCQs 33: Heart Failure\u00a0 - All About Cardiovascular System and Disorders","og_description":"\u26a1 Advanced Cardiology Series &#8211; Part 33 Interactive Cardiology MCQs #33 Post-Graduate Level Masterclass: Heart Failure &#038; Cardiomyopathies \ud83e\udec0 Live Scoreboard 0\/ 25 Correct Progress: 0\/25 Q1 According to the latest universal ACC\/AHA\/HFSA guidelines, foundational Guideline-Directed Medical Therapy (GDMT) for patients with symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF) relies on four primary pillars. [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-11-10T02:38:55+00:00","article_modified_time":"2026-11-10T02:38:59+00:00","og_image":[{"width":1340,"height":727,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Interactive Cardiology MCQs 33: Heart Failure\u00a0","datePublished":"2026-11-10T02:38:55+00:00","dateModified":"2026-11-10T02:38:59+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/"},"wordCount":2026,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/","url":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/","name":"Interactive Cardiology MCQs 33: Heart Failure\u00a0 - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg","datePublished":"2026-11-10T02:38:55+00:00","dateModified":"2026-11-10T02:38:59+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/11\/Interactive-Cardiology-MCQs-33-Heart-Failure-.jpg","width":1340,"height":727},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/interactive-cardiology-mcqs-33-heart-failure\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Interactive Cardiology MCQs 33: Heart Failure\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68080","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=68080"}],"version-history":[{"count":1,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68080\/revisions"}],"predecessor-version":[{"id":68082,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/68080\/revisions\/68082"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/68081"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=68080"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=68080"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=68080"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}